The Valley Desk

ArticleFrontiers in pharmacologyPublished

KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Cooper Norcross Health, Cooper Medical School of Rowan University, Rowan University. Affiliation source

Publication record

Type
Article
Venue
Frontiers in pharmacology
Published
Subject terms
Drug resistance; bcl-2; Bortezomib; Refractory; Mcl-1; Multiple Myeloma (Mm); Venetoclax
PubMed ID
39411073
PubMed Central ID
PMC11473443
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal